Clinical Trial Update: A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating different oral doses of PF-00489791 for adults with pulmonary arterial hypertension was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• PF-00489791 (PF-00489791)

Snippet

Sponsor: Pfizer | Conditions: Hypertension, Pulmonary | Phase 2 | Status: TERMINATED | Results posted: 2017-10-24